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Prominin-1+/CD133+ bone marrow-derived heart-resident cells
suppress experimental autoimmune myocarditis
Abstract
AIMS: Experimental autoimmune myocarditis (EAM) is a CD4(+) T cell-mediated mouse model of
inflammatory heart disease. Tissue-resident bone marrow-derived cells adopt different cellular
phenotypes depending on the local milieu. We expanded a specific population of bone marrow-derived
prominin-1-expressing progenitor cells (PPC) from healthy heart tissue, analysed their plasticity, and
evaluated their capacity to protect mice from EAM and heart failure. METHODS AND RESULTS: PPC
were expanded from healthy mouse hearts. Analysis of CD45.1/CD45.2 chimera mice confirmed bone
marrow origin of PPC. Depending on in vitro culture conditions, PPC differentiated into macrophages,
dendritic cells, or cardiomyocyte-like cells. In vivo, PPC acquired a cardiac phenotype after direct
injection into healthy hearts. Intravenous injection of PPC into myosin alpha heavy chain/complete
Freund's adjuvant (MyHC-alpha/CFA)-immunized BALB/c mice resulted in heart-specific homing and
differentiation into the macrophage phenotype. Histology revealed reduced severity scores for
PPC-treated mice compared with control animals [treated with phosphate-buffered saline (PBS) or crude
bone marrow at day 21 after MyHC-alpha/CFA immunization]. Echocardiography showed preserved
fractional shortening and velocity of circumferential shortening in PPC but not PBS-treated
MyHC-alpha/CFA-immunized mice. In vitro and in vivo data suggested that interferon-gamma
signalling on PPC was critical for nitric oxide-mediated suppression of heart-specific CD4(+) T cells.
Accordingly, PPC from interferon-gamma receptor-deficient mice failed to protect
MyHC-alpha/CFA-immunized mice from EAM. CONCLUSION: Prominin-1-expressing,
heart-resident, bone marrow-derived cells combine high plasticity, T cell-suppressing capacity, and
anti-inflammatory in vivo effects.
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Abstract 
Aim: Experimental autoimmune myocarditis (EAM) is a CD4+ T cell mediated mouse model 
of inflammatory heart disease. Tissue resident bone marrow-derived cells are supposed to 
adopt different cellular phenotypes depending on the local milieu. We expanded a specific 
population of bone marrow-derived prominin-1 expressing progenitor cells (PPC) from 
healthy heart tissue, analyzed their plasticity, and evaluated their capacity to protect mice 
from EAM and heart failure. 
Methods and results: PPC were expanded from healthy mouse hearts. Analysis of 
CD45.1/CD45.2 chimera mice confirmed bone marrow origin of the PPC. Depending on in 
vitro culture conditions, PPC differentiated into macrophages, dendritic cells or 
cardiomyocyte–like cells. In vivo, PPC acquired a cardiac phenotype after direct injection into 
healthy hearts. Intravenous injection of PPC into myosin alpha heavy chain/complete 
Freund’s adjuvant (MyHC-!/CFA)-immunized BALB/c mice resulted in heart-specific 
homing and differentiation into macrophage phenotype. Histology revealed reduced severity 
scores for PPC treated mice as compared with control animals (treated with PBS or crude 
bone marrow at day 21 after MyHC-!/CFA immunization). Echocardiography showed 
preserved fractional shortening and velocity of circumferential shortening in PPC but not 
PBS-treated MyHC-!/CFA immunized mice. In vitro and in vivo data suggested that 
interferon-" signalling on PPC was critical for nitric oxide mediated suppression of heart 
specific CD4+ T cells. Accordingly, PPC from interferon-" receptor deficient mice failed to 
protect MyHC-!/CFA immunized mice from EAM. 
Conclusions: Prominin-1 expressing, heart-resident, bone marrow-derived cells combine high 
plasticity, T cell suppressing capacity, and anti-inflammatory in vivo effects. 
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1. Introduction
Dilated cardiomyopathy is a common cause of heart failure and frequently results from viral 
infections1. Ongoing inflammation can be due to viral persistence and continuous release of 
inflammatory cytokines, or to an autoimmune response against cardiac tissues2-4. 
Experimental autoimmune myocarditis (EAM) is a CD4+ T cell mediated mouse 
model of post infectious cardiomyopathy and can be induced in susceptible strains by 
immunization with self-peptides derived from the myosin alpha heavy chain (MyHC-!) 
together with a strong adjuvant5,6, or by injection of activated, MyHC-! loaded dendritic 
cells7,8. Severity scores peak 21 days after immunization and the extent of inflammatory 
infiltrates resolves slowly thereafter. Nevertheless, many animals develop dilated 
cardiomyopathy on follow-up9. 
The healthy mouse heart contains between 5-8% CD45+ expressing, bone marrow-
derived cells. Amongst this population, a CD11b+ fraction is supposed to reflect immature 
monocyte-like cells9. The role of heart-resident bone marrow-derived cells in inflammatory 
heart disease, however, remains largely speculative. In the context of other inflammation 
models, recent data suggest that monocyte-like precursor cells can differentiate into diverse 
subpopulations of inflammatory cells such as dendritic cells and macrophages, depending on 
the cytokine/chemokine environment10-12. Other studies point to an amazing regenerative 
potential of bone marrow-derived tissue resident cells13. For example, in heart disease models 
there is evidence that bone marrow-derived precursor cells can adopt a tissue-specific 
phenotypes depending on the local milieu14.
We hypothesize that bone marrow-derived precursor cells with high plasticity can be 
expanded from healthy heart tissue. As a selection marker we chose prominin-1 (CD133), a 
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well-described indicator of haematopoietic, embryonic and adult progenitor cells15,16. Here, 
we describe the expansion of high numbers of immunomodulating prominin-1 expressing 
bone marrow-derived precursor cells (PPC) with multilineage differentiation potential from 
healthy mouse hearts. In addition, we provide in vivo evidence that PPC efficiently suppress 
EAM and heart failure development in MyHC-!/complete Freund’s adjuvant (CFA)
immunized mice. 
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2. Methods
2.1. Animals 
BALB/c mice, C57Bl/6-GFP transgenic mice (GFP under the control of #-actin promoter), 
and IFN-" !!" receptor knockout (IFN-"R-/-) mice were purchased from Jackson Laboratory and 
housed in a specific pathogen free environment. The local authorities approved the study and 
all experiments were performed in strict accordance with the US National Institutes of Health 
Guide for the Care and Use of Laboratory Animals and with the Swiss Federal Law.
2.2. Generation, expansion and in vitro differentiation of PPC
We generated and expanded PPC using a two-step protocol similar to that described by Tang 
et al.17. Mouse heart tissues were prepared according to reports17,18 with minor modifications 
(Supplementary Methods). We purified prominin-1+ cells from heart cell cultures by magnetic 
cell sorting or FACS sorting. To generate single cell derived clones, a single PPC-GFP+ cell 
was co-plated with PPC-GFP- feeder cells, cultured for 2-3 weeks. Cardiac differentiation was 
induced with 100 µM oxytocin (Sigma, Basel, Switzerland). Macrophage differentiation was 
induced with 10 ng/mL M-CSF (PeproTech, UK). Dendritic cell differentiation was induced 
with 10 ng/mL GM-CSF (PeproTech).
2.3. Immunization and treatment protocols
For immunization, all animals were transferred into conventional housing. Mice were injected 
subcutaneously with 100 $g/mouse of MyHC-!- (Ac-SLKLMATLFSTYASADOH) 
emulsified 1:1 with CFA on days 0 and 7, as descibed6. Control mice were immunized with 
CFA/PBS only. 
Depending on the experiment, PPC-GFP+ cells derived from GFP transgenic mice or PPC
labelled with fluorochrome conjugated nanocrystals (Quantum dots: QD, Molecular Probes, 
Invitrogen, Oregon, USA) were injected either intravenously (2x106 cells per mouse) at days 7
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and 14 after immunization, or directly into the left ventricle of anesthetized healthy animals 
(5x104 cells per mouse). The number of intravenously injected PPC recruited to the heart was 
calculated as percentage of PPC-QD+ detected by FACS, multiplied by the total number of 
cells isolated from heart tissue. The integration of intra-cardially injected PPC-GFP+ was 
analyzed using fluorescent microscopy on cryo- and paraffin-sections. Mean percentages of 
integrated PPC-GFP+, 2-3 weeks after cells injection, were calculated as mean percentage of 
GFP+ cardiomyocytes at the site of injection, multiplied by the total number of cells in the 
region of injection and number of analyzed slides.
To block in vivo nitric oxide (NO) production mice were intra-peritoneally injected daily with 
10 mg/kg body weight of L-NAME (Sigma) from day 7 until they were killed at day 21, as 
described19. Control mice received D-NAME (Sigma) under the same experimental 
conditions. Groups of L-NAME- and D-NAME-treated mice were injected with PPC on days 
7 and 14.
2.4. Generation of bone marrow chimera mice
5-8 weeks old C57/Bl6 (CD45.2+) mice were lethally irradiated with two doses of 6.5 Gy 
using a Gammatron (Co-60) system, and reconstituted with 2x107 donor bone marrow cells 
from C57/Bl6-Ly5.1 (CD45.1+) mice. After reconstitution all mice received prophylactic 
antibiotics in the drinking water and were housed in a specific pathogen-free environment.
2.5. Histology 
Animals were sacrificed at day 21 after the first immunization. Hearts were removed and 
stained with Hematoxylin-Eosin (HE). Myocarditis severity was assessed on HE sections and 
graded from 0 to 4, as described before8. 
2.6. RT-PCR 
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Samples were collected in Tri Reagent (Luzerna Chem, Luzern, Switzerland) and total RNA 
was isolated according to manufacturer’s recommendations. mRNA was reverse transcribed 
using Oligo d(T) primers (Invitrogen) and RevertAid M-MuLV Reverse Transcriptase 
(Fermentas, St. Leon-Rot, Germany). cDNA samples were amplified using the TaqPCR 
Master Mix Kit (Qiagen, Basel, Switzerland) and the appropriate oligonucleotides 
(Supplementary Table 1). Positive controls included R1 embryonic stem cells (kindly 
provided by Prof. A. M. Wobus, IPK, Gatersleben, Germany) for nanog, c-kit and Sca-1, and 
brain tissue of adult mouse for Islet-1 and nestin. 
2.7. Immunocytochemistry 
Cells were cultured on gelatine-coated cover slips. Fixation and immunostaining procedures 
were performed according to Wobus et al.,20 (see Supplementary Methods). 
2.8. Flow cytometry and cell sorting
Cells were incubated for 30 min on ice with the appropriate combination of fluorochrome 
conjugated and/or primary and secondary antibodies (Supplementary Methods), then washed 
and analyzed on a FACS Calibur (BD Bioscience) using FloJo 6.1.4 software (TreeStar, 
Ashland, USA). PPC were separated on a FACSVantage SE (BD Bioscience).
2.9. T cell lines, proliferation assays, and cytokine ELISA
For proliferation assays, CD4+ T cell lines were either stimulated for 24 hours in anti-CD3-
coated 96 well plates or for 48 hours on irradiated MyHC-! peptide pulsed splenocytes in 
RPMI 1640 medium (Cambrex BioWhittaker, Vervier, Belgium) with additives 
(Supplementary Methods). 105 CD4+ MyHC-!-specific T cell clones and 2x105 antigen 
presenting cells (APC)/well were co-cultured with titrating amounts of PPC. Proliferation was 
assessed by measuring 3H-thymidine incorporation (Amersham Biosciences, Otelfingen, 
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Switzerland). Nitrite (NO2-) levels reflecting NO production were determined using the Griess 
Reagent System (Promega, Madison, WI, USA). IFN-" and TNF-! were measured using 
commercially available OptEIATM Mouse Elisa systems (both BD Biosciences).
2.10. Functional analysis
Echocardiographic assessments were carried out as described6. For analysis we used healthy 
control mice, and animals immunized with MyHC-!/CFA, injected with either PPC or PBS.
2.11. Statistics
The Mann-Whitney U test was used for the evaluation of non-parametrical data. Proliferation 
responses and cytokine levels were compared using ANOVA and Student’s t-test.
CVR-2008-33R2
3. Results
3.1. Expansion of PPC from healthy hearts
To specifically enrich heart-resident monocyte precursor cells, we adopted a modified 
two-step protocol, originally described for the expansion of cardiac progenitor cells from heart 
cell suspensions17. Healthy adult heart contains up to 2% prominin-1+ cells (Supplementary 
fig. 1). Based on the hypothesis that the expansion of bone marrow-derived precursor cells 
critically depends on various tissue factors creating a specific milieu, we seeded the cell 
suspensions at high density (>106 cells per 60 mm culture dish) and screened proliferating 
cells for the expression of both bone marrow-specific and progenitor cell markers. After a few 
days of culture, we observed small, round, semi-attached and highly proliferating cells which 
contained 80-90% CD45+CD11b+ cells co-expressing the stem/progenitor cell marker 
prominin-1 (Fig. 1A). Prominin-1+ cells were then purified by cell sorting, re-plated onto 
gelatine-coated plates and expanded for another 5-6 passages. The resulting PPC were 
clonogenic; co-plating of single PPC-GFP+ cell together with 5x104 PPC-GFP- feeder cells 
resulted in highly proliferating clones (see Supplementary Fig. 1A). All PPC were 
CD11b+CD45+ and chemokine receptor (CXCR) 4 expressing cells (Fig. 1A, C, D). In 
addition, PPC co-expressed stem/progenitor cell markers, such as stem cell antigen (Sca) 1 
and c-kit (CD117) (Fig. 1A, E), suggesting a monocyte precursor phenotype. PPC however, 
did not express the endothelial/haematopoietic progenitor marker CD34 or the granulocyte 
specific marker Gr-1 (not shown). On the genetic level, PPC showed enhanced expression of 
genes characteristic for stem/progenitor cells such as nanog, Sca-1 and c-kit, and markers of 
early lineage precursors like Islet-1 and nestin (see Fig. 3A).  
Isolation of PPC from hearts of CD45.1/CD45.2 chimera mice confirmed the bone 
marrow origin of PPC (Fig. 1F). Importantly, the efficient generation of clonogenic PPC
critically required the presence of a heart-derived feeder cell layer. 
Thus, we have established an efficient in vitro system to specifically expand high
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numbers of clonogenic PPC with stem/progenitor and haematopoietic cell characteristic from 
mouse hearts.
3.2. Differentiation capacity of PPC
PPC co-expressed CD45 and CD11b, but no markers indicating a mature monocyte or 
macrophage phenotype such as F4/80 (Fig. 2A). In the presence of M-CSF, PPC lost their 
stem/progenitor characteristic gene expression pattern; they became F4/80- and major 
histocompatibility complex (MHC) class II-positive, acquired a large, flat morphology and 
showed granular cytoplasm and phagocytic activity (Fig. 2D, E). On the other hand, in the 
presence of GM-CSF, PPC expressed CD11c and MHCII and acquired a dendritic cell 
phenotype (Fig. 2F, G). 
The observation that PPC expressed transcription factors characteristic for the 
developing myocardium (Fig. 3B) prompted us to evaluate the capacity of PPC to differentiate 
into cardiomyocyte-like cells. To induce cardiac differentiation, we cultured PPC in the 
presence of oxytocin21,22. As illustrated in figure 3, oxytocin treated PPC formed clusters (Fig. 
3C), expressed genes characteristic for cardiomyocytes such as Nkx 2.5, cardiac actin, cardiac 
troponin (cTn) I, ! myosin heavy chain (MHC), #MHC, atrial natriuretic peptide (ANP) and 
myosin light chain (MLC) 2V23 (Fig. 3B), and produced the corresponding proteins (Fig. 3E-
H). Co-cultures of differentiated, GFP-expressing PPC together with adult, cell-tracker 
labelled rat cardiomyocytes resulted in spontaneous contraction of the clusters 
(Supplementary movie), excluding cell fusion between rat and GFP+ mouse cells (Fig. 3D; 
Supplementary fig. 3B).
In order to confirm the capacity of the PPC to differentiate into cardiomyocytes in 
vivo, 5x104 PPC-GFP+ were injected directly into the left ventricular wall of healthy heart. 
One day after injection, PPC were detectable as small, round, and prominin-1-expressing cells 
(Fig. 3I). Three weeks later, GFP expressing cells were clearly integrated into the myocardium 
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and co-expressed cardiomyocyte-specific markers, such as !-MHC, sarcomeric actin and cTnI 
(Fig. 3K-M). We determined that the region of cell insertion into the myocardium contained 
500-2500 of injected GFP+, which corresponds to 1-5% of the total number of injected PPC-
GFP+. Notably, none of GFP+ cells expressed vimentin or !SMA, specific for fibroblast 
differentiation (Fig. 3N, O). Importantly, PPC did not accumulate specifically in the healthy 
heart after intravenous injection (not shown). 
Taken together, these results demonstrate the capacity of PPC to differentiate into 
cardiomyocyte-like cells in vitro and in vivo and to integrate themselves into the myocardium 
of healthy mice after direct intra-cardial administration.
3.3. PPC suppress experimental autoimmune myocarditis
Autoimmune myocarditis development depends on the presence of heart-specific autoreactive 
CD4+ T cells24,25. The first inflammatory infiltrates develop 10 and 14 days after 
immunization and maximal disease scores are usually evident at days 20 to 239. Given the 
high plasticity of the PPC we queried how these cells affect the disease course of EAM. 
We immunized groups of BALB/c wild-type mice with the MyHC-! peptide together 
with CFA, and addressed the in vivo fate of PPC, labelled with fluorochrome-conjugated 
nanocrystals (Quantum-dots: QD), after intravenous administration at days 7 and 14 following 
immunization (2x106 of PPC-QD+/animal). PPC-QD+ homed to the hearts of immunized mice 
and were still detectable 2-3 weeks after injection (Fig. 4A, B). We detected 5x104-2x105 of 
PPC-QD+ among the total cell number in heart tissue suspensions in FACS analysis. This 
number corresponds to approximately 5% of injected PPC-QD+. Importantly, QD labelled 
cells accumulating within the inflamed heart gained the expression of macrophage markers 
F4/80 (A) and CD68 (B), but no fibroblast (collagen I; in C), granulocyte (Gr-1; in D) or 
cardiac markers (not shown). This suggests that in the inflammatory environment in vivo PPC
CVR-2008-33R2
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differentiated to a macrophage-like phenotype. No relevant homing to other organs was 
observed (not shown).
We next evaluated the effect of intravenously injected PPC on myocarditis severity in 
immunized mice. Control animals received either PBS or crude suspensions of bone marrow 
cells. Injection of PPC (Fig. 4E, G), but not PBS (Fig.4 F,G) or crude bone marrow cells (Fig. 
4G), suppressed the histological severity of myocarditis. Echocardiography showed preserved 
fractional shortening (Fig. 4I) and velocity of circumferential shortening (Fig. 4K) in PPC-
treated mice compared to control PBS-treated MyHC-!/CFA immunized mice. These data 
demonstrate that PPC injected during the acute phase of disease efficiently suppress EAM and 
prevent the progression to heart failure.
3.4. PPC suppress the expansion of heart-specific CD4+ T cells
As shown in Figure 4H, injection of PPC impaired the expansion of heart-specific, 
auto-reactive CD4+ T cells in vivo. CD4+ T cells were isolated at day 21 from immunized mice 
treated with either PPC or PBS. CD4+ T cells were then re-stimulated on MyHC-! pulsed 
antigen presenting cells. As illustrated in figure 4H CD4+ T cells from PPC-treated, MyHC-
!/CFA immunized mice show a markedly reduced recall response upon MyHC-! stimulation. 
This, together with the fact that PPC were injected 7 and 14 days after immunization (i.e. after 
the priming phase of T cells), illustrates the markedly impaired in vivo expansion of MyHC-!
specific T cells in PPC-treated mice.
Because the frequency of the pathogenic Th17 CD4+ T cell subset within the whole 
peripheral CD4+ T cell population largely exceeds 1-2% in the EAM model24, we specifically 
addressed the effect of the PPC on in vitro expanded, highly MyHC-! specific CD4+ T cell 
lines containing between 20 and 60% IL-17 producing T cells, together with 10-20% of IFN-"
producing T cells (Fig. 5A and not shown). As illustrated in Fig. 5B, PPC strongly suppressed 
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the proliferation of MyHC-! specific, activated CD4+ T cells in vitro and reduced the release 
of TNF-!, one of the key cytokines in myocarditis development26 (Fig. 5D). 
Given the fact that PPC differentiate to mature macrophages in the inflammatory
microenvironment in vivo (Fig. 4), we hypothesized that PPC mediate T cell suppression by 
NOS2 up-regulation and release of NO in vivo. Indeed, we observed markedly enhanced 
release of NO (Fig. 5E) in supernatants of T-cell/APC cultures in the presence of PPC. In 
addition, T cell responses were largely restored in the presence of the NOS inhibitor L-NAME 
(Fig. 5C), suggesting that PPC-mediated NO release indeed accounts for the observed 
suppression of heart-reactive T cells in vitro. The critical role of NO in the PPC mediated 
suppression of autoreactive T cell responses and myocarditis was confirmed in vivo. As 
shown in figure 6A-B, treatment of immunized and PPC injected mice with the non-specific 
NOS inhibitor L-NAME, but not with the inactive D-NAME, abolished the protective effects 
of PPC treatment.
Several lines of evidence suggest that IFN-" is critically involved in the up-regulation 
of NOS2 on activated monocytes/macrophages. We therefore hypothesized that IFN-"
signalling might also be critical for NOS2 induction in PPC within the inflammatory 
microenvironment. To address this question directly in vivo we treated MyHC-!/CFA 
immunized mice with PPC generated from hearts of IFN-"R-/- mice. As illustrated in Figure 
6C IFN-"R-/- PPC did not protect against myocarditis development.
Taken together, these data suggest PPC exert a direct inhibitory effect on heart-
specific autoreactive CD4+ T cells. This effect requires IFN-" signalling on PPC and is 
mediated by NO.
CVR-2008-33R2
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4. Discussion 
We have developed an efficient in vitro system to expand high numbers of a specific 
population of bone marrow-derived prominin-1 expressing monocyte precursor cells from 
healthy heart tissue with immunomodulating and multilineage differentiation capacity. PPC
homed to the inflamed heart, protected against EAM and inhibited pathogenic CD4+ T cell 
responses. Importantly, the PPC are self-renewing, clonogenic, and exhibit a capacity to 
differentiate not only to macrophage/monocyte or dendritic cell phenotypes, but also to 
cardiomyocyte-like cells depending on the cell culture conditions and applied signalling. 
From this point of view, our cells fulfil the required criteria for multipotent progenitor cells 
and share many features of mesenchymal stem cells (MSC)27. 
EAM is a CD4+ T cell mediated disease. Th17 cells are critical for the induction of 
heart specific autoimmunity, whereas Th1 and Th2 subsets are supposed to modulate the 
disease phenotype24,28. Our data show that PPC suppress the expansion of autoreactive CD4+
T cells in vivo and in vitro. Mechanistically, the protective capacity of the PPC depends on 
their differentiation to a monocyte/macrophage-like phenotype suppressing heart-specific 
autoreactive CD4+ T cells IFN-"-dependently by release of NO. This observation is in line 
with earlier studies suggesting immunomodulatory effects of NO, including the induction of 
reversible growth arrest in proliferating human Th1 and Th2 T cell lines29. T cell suppression 
could also be observed in the absence of antigen-presenting cells, if T cells were stimulated by 
plate bound anti-CD3 antibodies (not shown), suggesting direct NO release from PPC. PPC, 
injected into MyHC-!/CFA immunized mice differentiated into monocyte-like cells up-
regulating NOS2 synthetase. Importantly, this effect was dependent upon IFN-", suggesting 
that the immunomodulating effects of PPC require the presence of IFN-"% released by Th1 
cells as part of a heterogeneous autoreactive CD4+ T cell response, CD8+ T cells24 or natural 
killer (NK) cells. In autoimmune myocarditis, autoreactive heart infiltrating CD4+ T cells 
belong to the Th17 phenotype. Accordingly, only minimal IFN-" is released from CD4+ T 
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cells within the acutely inflamed heart24. However, it has been shown very recently that heart-
infiltrating CD8+ T cells release IFN-" and mediate non-specific bystander suppression of 
autoreactive Th17 cells by induction of NOS2 and NO release from macrophages24. 
Nevertheless, we cannot exclude other PPC mediated anti-inflammatory mechanisms and 
further studies are certainly needed to clarify these issues. 
Given the progenitor cell characteristics of the PPC it should be mentioned that human 
MSC are also supposed to exert anti-inflammatory effects by changing the cytokine secretion 
profile of dendritic cells, naive and effector T cells and NK cells30. In the animal system, MSC 
reduced EAM severity in rats31,32. Interestingly, Sato et al.32 recently showed that MSC induce 
a NO-dependent reversible T cell growth arrest in vitro. In humans, cell-based 
immunomodulatory treatments are mostly applied to patients with autoimmune disease such 
as severe systemic lupus erythematosus33 or as adjuvant for severe graft versus host disease 
after bone marrow transplantation in patients with leukemia34. In both cases however, the 
precise mechanisms responsible for the beneficial effect of cell-based immune-modulating 
treatment remain unknown. The PPC provide some explanation on the cellular level as to how 
such modulation of the immune system could work. To our knowledge and in contrast to the 
heterogeneous population of MSC these PPC are the first haematopoietic progenitor cell with 
such well-defined properties.
Appropriate timing of PPC injections was essential for the prevention of EAM. These 
findings are in line with observations on the effects of embryonic stem cells in a model of 
viral myocarditis35 or MSC in a rat model of acute myocarditis36. Our data suggest that the 
protective effects of PPC depend rather on their immunomodulatory capacity than on their 
regenerative potential. Injection of PPC resulted in the differentiation of macrophages/mature 
monocytes in the inflammatory environment in vivo, and we found no evidence for heart-
specific differentiation. On the other hand, in the microenvironment of a healthy heart PPC
integrated themselves into the myocardium and differentiated into cardiomyocytes. 
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Nevertheless, the multilineage differentiation capacity of the PPC offers the potential to 
develop strategies that specifically promote tissue regeneration from PPC in the inflamed 
heart. Potential strategies might include combined PPC treatment/cytokine targeting, and 
epigenetic or genetic manipulation of in vitro expanded PPC. 
PPC represent a population of prominin-1 expressing, bone marrow-derived heart-
resident cells. Prominin-1 expressing cells are also present in bone marrow of healthy animals 
but show no comparable regenerative and immunomodulatory capacity (unpublished 
observation). We believe that either heart-specific tissue factors, the specific 
microenvironment due to the disintegration of whole heart tissue, or inflammatory processes 
are critical for the activation and expansion of immunomodulatory and regenerative PPC. If it 
is possible to precisely specify these conditions and to adopt them on crude bone marrow, it 
might become feasible to isolate huge numbers of immunomodulatory/regenerative cells from 
bone marrow. This would be a further step toward an innovative treatment strategy against 
inflammatory heart diseases.
In conclusion, the healthy mouse heart contains a specific population of prominin-1+
bone marrow-derived heart-resident precursor cells that can be expanded from disintegrated 
cardiac tissue. These cells combine regenerative and immunomodulatory capacities and 
suppress EAM in mice. If it will become feasible to specifically control the differentiation 
potential of the PPC within the specific cytokine/chemokine milieu of the chronically 
inflamed heart, PPC based treatment strategies could become a promising therapeutic option 
for devastating inflammatory heart diseases in the future. 
CVR-2008-33R2
17
Acknowledgment
We thank Heidi Bodmer for technical assistance, Rene Marty, Nora Mauermann, and 
Christoph Berger for helpful discussions, Ulrich Schneider for animal care, Claire Marigande 
for providing us with rat cardiomyocytes, Verena Jaggin for cell-sorting, Profs. Therese 
Resink and Ed Palmer for critical reading.
Funding sources
The generous support of the Gebert-Rüf Foundation (U.E.; H.Z.) is gratefully acknowledged. 
U.E. holds a Swiss National Foundation professorship.
Disclosures
None
CVR-2008-33R2
18
References 
1. Feldman AM, McNamara D. Myocarditis. N Engl J Med 2000;343:1388-1398.
2. Rose NR. Infection, mimics, and autoimmune disease. J Clin Invest 2001;107:943-944.
3. Fairweather D, Kaya Z, Shellam GR, Lawson CM, Rose NR. From infection to 
autoimmunity. J Autoimmun 2001;16:175-186.
4. Eriksson U, Penninger JM. Autoimmune heart failure: new understandings of pathogenesis. 
Int J Biochem Cell Biol 2005;37:27-32.
5. Neu N, Rose NR, Beisel KW, Herskowitz A, Gurri-Glass G, Craig SW. Cardiac myosin 
induces myocarditis in genetically predisposed mice. J Immunol 1987;139:3630-3636.
6. Eriksson U, Kurrer MO, Schmitz N, Marsch SC, Fontana A, Eugster HP et al. Interleukin-
6-deficient mice resist development of autoimmune myocarditis associated with impaired 
upregulation of complement C3. Circulation 2003;107:320-325.
7. Eriksson U, Ricci R, Hunziker L, Kurrer MO, Oudit GY, Watts TH et al. Dendritic cell-
induced autoimmune heart failure requires cooperation between adaptive and innate 
immunity. Nat Med 2003;9:1484-1490.
8. Marty RR, Dirnhofer S, Mauermann N, Schweikert S, Akira S, Hunziker L et al. MyD88 
signaling controls autoimmune myocarditis induction. Circulation 2006;113:258-265.
9. Afanasyeva M, Georgakopoulos D, Belardi DF, Ramsundar AC, Barin JG, Kass DA et al.
Quantitative analysis of myocardial inflammation by flow cytometry in murine autoimmune 
myocarditis: correlation with cardiac function. Am J Pathol 2004;164:807-815.
10. Pluchino S, Zanotti L, Rossi B, Brambilla E, Ottoboni L, Salani G et al. Neurosphere-
derived multipotent precursors promote neuroprotection by an immunomodulatory 
mechanism. Nature 2005;436:266-271.
11. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL et al.
The healing myocardium sequentially mobilizes two monocyte subsets with divergent and 
complementary functions. J Exp Med 2007;204:3037-3047.
CVR-2008-33R2
19
12. Arnold L, Henry A, Poron F, Baba-Amer Y, van Rooijen N, Plonquet A et al.
Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory 
macrophages to support myogenesis. J Exp Med 2007;204:1057-1069.
13. Rota M, Kajstura J, Hosoda T, Bearzi C, Vitale S, Esposito G et al. Bone marrow cells 
adopt the cardiomyogenic fate in vivo. Proc Natl Acad Sci U S A 2007;104:17783-17788.
14. Xu Q. Stem cells and transplant arteriosclerosis. Circ Res 2008;102:1011-1024.
15. Kania G, Corbeil D, Fuchs J, Tarasov KV, Blyszczuk P, Huttner WB et al. Somatic stem 
cell marker prominin-1/CD133 is expressed in embryonic stem cell-derived progenitors. Stem 
Cells 2005;23:791-804.
16. Mizrak D, Brittan M, Alison MR. CD133: molecule of the moment. J Pathol 2008;214:3-
9.
17. Tang YL, Shen L, Qian K, Phillips MI. A novel two-step procedure to expand cardiac 
Sca-1+ cells clonally. Biochem Biophys Res Commun 2007;359:877-883.
18. Messina E, De Angelis L, Frati G, Morrone S, Chimenti S, Fiordaliso F et al. Isolation 
and expansion of adult cardiac stem cells from human and murine heart. Circ Res
2004;95:911-921.
19. Eriksson U, Kurrer MO, Bingisser R, Eugster HP, Saremaslani P, Follath F et al. Lethal 
autoimmune myocarditis in interferon-gamma receptor-deficient mice: enhanced disease 
severity by impaired inducible nitric oxide synthase induction. Circulation 2001;103:18-21.
20. Wobus AM, Guan K, Yang HT, Boheler KR. Embryonic stem cells as a model to study 
cardiac, skeletal muscle, and vascular smooth muscle cell differentiation. Methods Mol Biol
2002;185:127-156.
21. Matsuura K, Nagai T, Nishigaki N, Oyama T, Nishi J, Wada H et al. Adult cardiac Sca-1-
positive cells differentiate into beating cardiomyocytes. J Biol Chem 2004;279:11384-11391.
CVR-2008-33R2
20
22. Oyama T, Nagai T, Wada H, Naito AT, Matsuura K, Iwanaga K et al. Cardiac side 
population cells have a potential to migrate and differentiate into cardiomyocytes in vitro and 
in vivo. J Cell Biol 2007;176:329-341.
23. Lints TJ, Parsons LM, Hartley L, Lyons I, Harvey RP. Nkx-2.5: a novel murine 
homeobox gene expressed in early heart progenitor cells and their myogenic descendants. 
Development 1993;119:969.
24. Rangachari M, Mauermann N, Marty RR, Dirnhofer S, Kurrer MO, Komnenovic V et al.
T-bet negatively regulates autoimmune myocarditis by suppressing local production of 
interleukin 17. J Exp Med 2006;203:2009-2019.
25. Donermeyer DL, Beisel KW, Allen PM, Smith SC. Myocarditis-inducing epitope of 
myosin binds constitutively and stably to I-Ak on antigen-presenting cells in the heart. J Exp 
Med 1995;182:1291-1300.
26. Bachmaier K, Pummerer C, Kozieradzki I, Pfeffer K, Mak TW, Neu N et al. Low-
molecular-weight tumor necrosis factor receptor p55 controls induction of autoimmune heart 
disease. Circulation 1997;95:655-661.
27. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR et 
al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:41-
49.
28. Sonderegger I, Rohn TA, Kurrer MO, Iezzi G, Zou Y, Kastelein RA et al. Neutralization 
of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J 
Immunol 2006;36:2849-2856.
29. Eriksson U, Egermann U, Bihl MP, Gambazzi F, Tamm M, Holt PG et al. Human 
bronchial epithelium controls TH2 responses by TH1-induced, nitric oxide-mediated STAT5 
dephosphorylation: implications for the pathogenesis of asthma. J Immunol 2005;175:2715-
2720.
CVR-2008-33R2
21
30. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune 
cell responses. Blood 2005;105:1815-1822.
31. Okada H, Suzuki J, Futamatsu H, Maejima Y, Hirao K, Isobe M. Attenuation of 
autoimmune myocarditis in rats by mesenchymal stem cell transplantation through enhanced 
expression of hepatocyte growth factor. Int Heart J 2007;48:649-661.
32. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T et al. Nitric oxide plays a critical 
role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007;109:228-
234.
33. Traynor AE, Schroeder J, Rosa RM, Cheng D, Stefka J, Mujais S et al. Treatment of 
severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-
cell transplantation: a phase I study. Lancet 2000;356:701-707.
34. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H et al.
Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. 
Transplantation 2006;81:1390-1397.
35. Malek S, Kaplan E, Wang JF, Ke Q, Rana JS, Chen Y et al. Successful implantation of 
intravenously administered stem cells correlates with severity of inflammation in murine 
myocarditis. Pflugers Arch 2006;452:268-275.
36. Ohnishi S, Yanagawa B, Tanaka K, Miyahara Y, Obata H, Kataoka M et al.
Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a 
rat model of acute myocarditis. J Mol Cell Cardiol 2007;42:88-97.
CVR-2008-33R2
22
Figure legends 
Figure 1. Characteristic of PPC. A, FACS analysis of heart-derived cells before separation of 
prominin-1+ cells. B, Morphology of PPC. C-E, Immunofluorescence showed that PPC co-
expressed CD45 (C), CXCR4 (D) and Sca-1 (E). Hoechst 33342 (blue) was used to visualize 
cell nuclei. Bars = 20µm. (F) In CD45.1/CD45.2 chimera mice population of donor CD45.1 
cells replaced CD45.2 of host origin within the heart. PPC from hearts of CD45.1/CD45.2 
chimera confirmed the bone marrow origin of the PPC. 
Figure 2. Sorted PPC differentiated into macrophage- and dendritic-like cells in vitro. A-C, 
Undifferentiated prominin-1+/CD45+/CD11b+ cells stained negative for F4/80, CD11c and 
MHCII (A), and did not show phagocyte activity (B, C). D-E, PPC exposed to M-CSF co-
expressed F4/80, CD11b, and CD45, and became large, oval cells with the capacity to 
phagocyte bacteria (E). F-G, PPC exposed to GM-CSF started to express CD11c and MHCII 
(F), and changed the morphology towards dendritic cell phenotypes (G). Hoechst 33342 
(blue) was used to visualize cell nuclei. Bars = 20µm. 
Figure 3. Sorted PPC differentiated to cardiomyocyte-like cells. A, mRNA levels of stem and 
progenitor cell specific markers: nanog, sca-1, c-kit, Islet-1, nestin. B, mRNA levels of genes 
specific for developing and mature cardiomyocytes like GATA4, Nkx2.5, MEF-2C, MEF-2D, 
TEF-!"# $%&'(%$# %$)(*"# $+*,"# -./0"# 1./0"#234"#.50-2V, in sorted PPC (P+), and after 
differentiation into cardiac (C) lineages. (+) = positive control, H = adult heart. 
C-H, Oxytocin induced cardiac in vitro differentiation of PPC. PPC formed cardiomyocyte-
like clusters (C). Co-culture of PPC-GFP+ cells with cell tracker red CMTPX-labelled adult 
rat cardiomyocytes showed no cell fusion between mouse and rat cells (D). Cardiomyocyte 
like cells, differentiated from PPC 678&6996'# -./0# :;<"# $+*,# :=<"# %*'# 9>?@6'# %# )A8($%B#
pattern of sarcomeric actin (G) and titin (H). 
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I-O, PPC injected into healthy hearts were integrated in the myocardium. Prominin-1+/GFP+ 
cells were found in clusters one day post injection (I), and acquired the cardiac phenotype 
three weeks after injection expressing !MHC (K), sarcomeric actinin (L), cTnI (M), but not 
vimentin (N) or !SMA (O). Hoechst 33342 (blue) was used to visualize cell nuclei. Bars = 
20µm.
Figure 4. PPC suppressed EAM. A-D, Intravenously injected PPC-QD+ (2x106 cells per 
mouse at days 7 and 14) homed to the hearts of MyHC-!/CFA immunized mice, and 21 days 
post immunization showed characteristic of macrophages expressing F4/80 (A) and CD68 
(B), but not collagen I+ fibroblasts (C) or Gr-1+ granulocytes (D). E-F, Heart sections from 
MyHC-!/CFA immunized mice treated either with PPC (E) or PBS (F). G, Myocarditis scores 
of individual immunized mice treated with PPC (black triangles), PBS (white squares), or 
bone marrow suspensions (red circles), analyzed 21 days after immunization. Median values 
for each group are shown. H, Proliferation assay of CD4+ T cells isolated from spleens of 
MyHC-!/CFA immunized mice treated with PPC (black triangles) or PBS (white squares). 
Means ± SD of 23 individual mice (9 per experimental and control group, 5 per bone marrow 
treated mice) are shown. I-K, Echocardiography of mice treated with PBS or PPC after 
MyHC-!/CFA immunization. Fractional shortening (FS, %) (I), and velocity of 
circumferential shortening (VCFC; circ/s) (K) were determined 34 days after immunization 
on PBS- or PPC-treated mice and on healthy mice used as controls. Average values ± SD of 6 
individual mice are shown.
Figure 5. PPC inhibited the proliferation of MyHC-! specific Th17 T cell in vitro. A, FACS 
analysis confirmed that T cell lines contained between 20 to 60% of IL-17 producing CD4+ T 
cells. B, Titrating amounts of PPC suppressed the proliferation of MyHC-! specific CD4+
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T17 cells. CD4+ T17 cells were re-stimulated with the MyHC-! antigen on irradiated APC 
cells. C, The NOS inhibitor L-NAME prevented PPC mediated suppression of antigen re-
stimulated MyHC-! specific CD4+ T17 cells. TNF-! (D) and IFN-" (F) production of in vitro
MyHC-! antigen re-stimulated CD4+ T cells are reduced in the presence of PPC. E, Enhanced 
NO production in supernatants of T cell/APC cultures in the presence of PPC. Each bar 
represents the mean ± SD from 5 different culture wells. 
Figure 6. NO mediated the suppression of heart specific CD4+ T cells in vivo. A, Proliferation 
assay of CD4+ T cells isolated from spleens of MyHC-!/CFA immunized mice treated with 
PPC (at days 7 and 14) and D-NAME (daily between days 7-21; grey circles), or with PPC (at 
days 7 and 14) and L-NAME (daily between days 7-21; black squares). Means ± SD of 8 
individual mice are shown. B, Myocarditis scores of individual immunized mice analyzed at 
day 21, after treatments with PPC (at days 7 and 14) and D-NAME (daily between days 7-21; 
grey circles), or with PPC (at days 7 and 14) and L-NAME (daily between days 7-21; black 
squares). C, Myocarditis scores of individual wt (INF-"R+/+) mice 21 days after MyHC-!/CFA 
immunization, after treatments, at days 7 and 14, with PPC derived from the hearts of IFN-"R
-/- mice (grey circles), with PPC derived from the wt hearts of IFN-"R+/+ mice (black triangles), 
or with PBS as control (white squares). Median values for each group are shown.
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Supplementary online material 
Methods
Generation, expansion and in vitro differentiation of PPC 
A slightly modified two-step protocol was used to generate and expand bone 
marrow-derived prominin-1 expressing progenitor cells (PPC) from healthy heart tissue, 
as descibed1-3. Hearts from 1- or 6-8 weeks old mice were collected, dissected into small 
pieces and digested for 20-50 min at 37&C in collagenase blendzyme 3 (Liberase no 3; 
Roche, Mannheim, Germany). Cell suspensions were filtered through a 70 µm nylon 
mesh (BD Biosciences, Switzerland) and plated onto gelatine-coated cell culture plates in 
Culture Expansion Medium (CEM) composed of Iscove`s modified Dulbecco`s medium 
(IMDM; Sigma, Switzerland), supplemented with 100 µM #-mercaptoethanol, 1:100 
penicillin-streptomycin, and 10% heat-inactivated foetal calf serum (all from Gibco-
Invitrogen, UK). 48-72 hours after plating, non-attached cells and fragments were 
removed and the remaining tissue explants were cultured in CEM at 37&C in a humidified 
atmosphere with 5% CO2. After 2–3 weeks, small, round cells migrated above the 
fibroblast layer formed from adherent fragments. PPC were isolated by positive selection 
with anti-prominin-1-PE antibody (eBioscience, California, USA) and magnetic anti-PE-
microbeads (Miltenyi Biotec, Germany) or by cell sorting (see below). PPC were plated 
onto gelatine-coated cell culture plates in CEM and expanded for 4-6 passages. Medium 
was exchanged every 3 days. 
To generate a single cell-derived clone, single prominin-1+ PPC-GFP+ cell was co-plated 
together with 5x104 PPC-GFP- feeder cells.
Supplementary Material - Other
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For differentiation experiments, PPC were re-plated onto gelatine-coated cell culture 
plates in CEM supplemented with 2% FCS. Cardiac differentiation was induced with 100 
µM oxytocin (Sigma). Macrophage differentiation was induced with 10 ng/mL M-CSF 
(PeproTech, UK) and dendritic cell differentiation with 10 ng/mL GM-CSF (PeproTech).
Flow cytometry
Hearts were perfused, excised, dissected into small pieces and digested as 
described above. Single cell suspensions were obtained by straining through 70 µm nylon 
mesh. Cells were washed twice with 50 mL FACS buffer (1% FCS, 1 mM EDTA in 
phosphate buffered saline-PBS, all from Gibco) and incubated 30 min on ice with the 
appropriate combination of fluorochrome conjugated and/or primary and secondary 
antibodies. Labelled cells were washed and re-suspended in FACS buffer. The following 
antibodies and dilutions were used: 1) Primary antibodies: rabbit IgG anti-CXCR4 1:100 
(Abcam, Cambridge, UK), goat IgG anti-Sca-1 (R&D Systems, Abingdon, UK) 1:200. 2) 
Secondary antibodies: AlexaFluor488 chicken anti-rabbit IgG, AlexaFluor488 chicken 
anti-goat IgG (all 1:100; all from Molecular Probes, Invitrogen, Oregon, USA). 3) 
Fluorochrome conjugated antibodies: anti-CD45-PE 1:400, anti-CD11b-APC 1:400, anti-
F4/80-PE 1:400 (all from BD Bioscience), anti-prominin-1-PE (eBioscience). Cells were 
analyzed on a FACS Calibur (BD Bioscience) using FloJo 6.1.4 software (TreeStar, 
Ashland, USA). For PPC sorting, cells were stained with anti-prominin-1-PE 
(eBioscience) antibody and separated on FACSVantage SE (BD Bioscience).
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For intracellular cytokine analysis, cells were re-stimulated for 4 hours with 50 ng/mL 
phorbol myristyl acetate and 500 ng/mL ionomycin in the presence of 10 $g/mL 
Brefeldin A (Sigma). Cytokines of interest were stained using the Cytofix/Cytoperm kit 
(BD Pharmingen) and the appropriate anti-cytokine antibodies (BD Pharmingen) 
according to the protocols provided by the manufacturer.
Immunocytochemistry
Cells were cultured on gelatine-coated cover slips. For immunohistochemistry, cells were 
fixed either in PBS containing 4% paraformaldehyde for 20 minutes at room 
temperature or with methanol:acetone (7:3) for 10 minutes at -20°C, as described4. PBS 
supplemented with 1% BSA was used as blocking solution and Hoechst 33342 (5 µg/ml) 
was used to label nuclei. The following primary antibodies and dilutions were used: 
mouse IgG anti-smooth muscle actin (Sigma) 1:1000, goat IgG anti-vimentin (Sigma) 
1:100, rat IgG anti-prominin-1 (Chemicon, Hofheim, Germany) 1:100, rabbit IgG anti-
CXCR4 (Abcam) 1:100, anti-CD45-PE (BD Biosciences) 1:400, mouse IgG anti-
sarcomeric actinin 1:100, mouse IgG anti-titin 1:100 (both from Sigma), mouse IgG anti-
myosin heavy chain alpha (Abcam) 1:200, mouse IgG anti-cardiac troponin I (Abcam) 
1:200, rabbit IgG anti-collagen I (Sigma), goat IgG anti-Sca-1 (R&D Systems), anti-
CD11b-APC (BD Biosciences). The following secondary antibodies and dilutions were 
used: AlexaFluor488 chicken anti-goat IgG 1:100, AlexaFluor546 rabbit anti-goat IgG 
1:600, AlexaFluor488 chicken anti-mouse IgG 1:100, AlexaFluor546 rabbit anti-mouse 
IgG 1:600, AlexaFluor546 goat anti-mouse IgG 1:600, AlexaFluor546 donkey anti-rat 
IgG 1:600, AlexaFluor488 chicken anti-rabbit IgG 1:100, AlexaFluor546 goat anti-rabbit 
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IgG 1:600, AlexaFluor350 donkey anti-mouse IgG 1:100 (all from Molecular Probes, 
Invitrogen). 
Adult rat cardiomyocytes were labelled with Cell Tracker Red CMTPX (Molecular 
Probes, Invitrogen) according to the instructions of the manufacturer.
For phagocytosis assays, Escherichia coli BioParticles Alexa Fluor 488- or Texas Red-
conjugated (Molecular Probes, Invitrogen) were used according to the instructions of the 
manufacturer. Samples were analyzed using an Axiophot fluorescence microscope and a 
LSM 510 META confocal laser-scanning microscope (both Carl Zeiss, Jena, Germany).
T cell lines, proliferation assays, and cytokine ELISA
T cells were isolated using CD4 specific magnetic beads (Miltenyi Biotec, Germany). 
CD4+ T cells from MyHC-!-CFA immunized mice were re-stimulated in vitro on 
irradiated antigen presenting cells (APC) for 7 days, and maintained in a resting phase for 
7 days in the presence of 2 $g/mL IL-2 and 10 $g/mL IL-23 to generate highly MyHC-!
specific Th17 enriched T cell lines. 
For proliferation assays, CD4+ T cell lines were either stimulated for 24 hours in anti-
CD3 (BD Biosciences) coated 96 well plates or for 48 hours on irradiated MyHC-!
peptide pulsed splenocytes in RPMI 1640 medium (Cambrex BioWhittaker, Vervier, 
Belgium) supplemented with 10% FBS, 1:100 penicillin/streptomycin, 100 mM non 
essential amino acids, 100 mM sodium pyruvate, 50mM #-mercaptoethanol (all from 
Gibco). 105 CD4+ MyHC-!-specific T cell clones/2x105 APC/well were co-cultured with 
titrating amounts of PPC. Proliferation was assessed by measuring 3H-thymidine 
incorporation (Amersham Biosciences, Otelfingen, Switzerland). Supernatants were 
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collected after 48h. Nitrite (NO2-) levels reflecting NO production were determined using 
the Griess Reagent System (Promega, Madison, WI, USA). IFN-" and TNF-! were 
measured using commercially available OptEIATM Mouse Elisa systems (both BD 
Biosciences).
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Supplementary table 1
Primer sequences, size of the amplified products and annealing temperatures (Tm).
Analyzed gene Forward primer Reverse primer Prod Tm
Alpha-MHC ctgctggagaggttattcctc ggaagagtgagcggcgcatcaagg 302 bp 60&C
ANP ttggcttccaggccataattg aagagggcagatctatcgga 99 bp 53&C
Beta-MHC gccaacaccaacctgtccaagttc tgcaaaggctccaggtctgagggc 205 bp 60&C
Beta-tubulin ggaacatagccgtaaactgc tcactgtgcctgaacttacc 319 bp 60&C
Cardiac actin ctgagatgtctctctctctcttag acaatgactgatgagagatg 99 bp 55&C
Cardiac troponin I 
(cTnI)
aaagtggatgaagagagata attcttgcgccagtctccca 266 bp 54°C
c-kit gacgtcatgaagacttgctg gacagcagcaaagcctgttgg 269 bp 60&C
GATA-4 ctgtcatctcactatgggca ccaagtccgagcaggaattt 259 bp 55&C
Islet-1 gtttgtacgggatcaaatgc atgctgcgtttcttgtcctt 503 bp 60&C
MEF-2C agcaagaatacgatgccatc gaaggggtggtggtacggtc 431/311 bp 55&C
MEF-2D tgggaatggctatgtcagtg ctggtaatctgtgttgtagg 352/331 bp 53&C
MLC-2V tgtgggtcacctgaggctgtggttcag gaaggctgactatgtccgggagatgc 190 bp 60&C
Nanog agggtctgctactgagatgctctgca caaccactggtttttctgccaccg 364 bp 60&C
Nestin ctaccaggagcgcgtggc tccacagccagctggaactt 219 bp 60&C
Nkx2.5 cgacggaagccacgcgtgct ccgctgtcgcttgcacttg 180 bp 60&C
Sca-1 actgtgcctgcaaccttgtctgaga gtccaggtgctgcctccatt 322 bp 62°C
TEF-1 aagacgtcaagccctttgtg aaaggagcacactttggtgg 479 bp 53&C
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Supplementary figures
Supplementary figure 1. FACS analysis of gated cell suspensions from adult heart tissue 
(A). The gated region matches a distinct population of cells observed in FSC/SSC dot 
plots of heart tissue cells (B).
Supplementary figure 2. Single PPC-GFP+ co-plated with PPC-GFP- feeder cells 
generated clone (A). B-F, PPC-GFP+ of single derived clones (B) and upon stimulation 
with oxytocin differentiated into !MHC expressing cardiomyocytes (C). D, GFP+ cells 
with phagocytic activity generated in M-CSF stimulated cultures. Hoechst 33342 (blue) 
was used to visualize cell nuclei. Bars = 20µm.
Supplementary figure 3. PPC differentiate into beating cardiomyocytes. A, PPC-GFP+ 
co-cultured with adult rat cardiomyocytes generate beating clusters (see Supplementary 
movie). B, Co–culture of red cell tracker stained rat cardiomyocytes with PPC-GFP+ 
excludes cell fusion in vitro (B).
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